High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients

Transplant International

Volumn 24, Issue 5, 2011, Pages 425-432

  Saner, Fuat H ^a   Neumann, Till ^a   Canbay, Ali ^a   Treckmann, Juergen W ^a   Hartmann, Matthias ^a   Goerlinger, Klaus ^a   Bertram, Stefanie ^a   Beckebaum, Susanne ^a   Cicinnati, Vito ^a   Paul, Andreas ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Brain natriuretic peptide; Cirrhotic cardiomyopathy; Intensive care; Liver transplantation

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; LIVER ENZYME;

ADULT; ARTICLE; CONTROLLED STUDY; DIALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEMODYNAMICS; HUMAN; INTENSIVE CARE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYSTOLIC DYSFUNCTION;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; HUMANS; INTENSIVE CARE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; SYSTOLE;

EID: 79953785771     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01219.x     Document Type: Article

References (34)

1. Albillos A, Rossi I, Cacho G, et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol 1995; 268: G459.
2. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32: 1025.
3. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776.
4. Henriksen JH, Moller S. Cardiac and systemic haemodynamic complications of liver cirrhosis. Scand Cardiovasc J 2009; 43: 218.
5. Rayes N, Bechstein WO, Keck H, Blumhardt G, Lohmann R, Neuhaus P. Cause of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralbl Chir 1995; 120: 435.
6. Franco D, Vons C, Traynor O, de Smadja C. Should portosystemic shunt be reconsidered in the treatment of intractable ascites in cirrhosis? Arch Surg 1988; 123: 987.
7. Pattynama PM, van Hoek B, Kool LJ. Inadvertent arteriovenous stenting during transjugular intrahepatic portosystemic shunt procedure and the importance of hepatic artery perfusion. Cardiovasc Intervent Radiol 1995; 18: 192.
8. Torregrosa M, Aguade S, Dos L, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42: 68.
9. Moller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001; 36: 785.
10. Pozzi M, Redaelli E, Ratti L, et al. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol Dietol 2005; 51: 179.
11. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131.
12. Grodecki PV, Klein AL. Pitfalls in the echo-Doppler assessment of diastolic dysfunction. Echocardiography 1993; 10: 213.
13. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825.
14. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379.
15. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367.
16. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52: 1511.
17. Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol 2005; 20: 1115.
18. Fegler G. Measurement of cardiac output in anaesthetized animals by a thermodilution method. Q J Exp Physiol Cogn Med Sci 1954; 39: 153.
19. Erbel R, Neumann T, Zeidan Z, Bartel T, Buck T. Echocardiography diagnosis of diastolic heart failure. Herz 2002; 27: 99.
20. Ogawa Y, Nakao K, Mukoyama M, et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res 1991; 69: 491.
21. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl 2002; 8: 690.
22. Fukazawa K, Gologorsky E, Manmohansingh V, Nishida S, Vigoda MM, Pretto Jr EA. Is the immediate reversal of diastolic dysfunction of cirrhotic cardiomyopathy after liver transplantation a sign of the metabolic etiology? Liver Transpl 2009; 15: 1417.
23. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000; 6: S44.
24. Aggarwal S, Kang Y, Freeman J, DeWolf AM, Begliomini B. Is there a post-reperfusion syndrome? Transplant Proc 1989; 21: 3497.
25. Bandara M, Gordon FD, Sarwar A, et al. Successful outcomes following living donor liver transplantation for portopulmonary hypertension. Liver Transpl 2010; 16: 983.
26. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10: 174.
27. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002; 30: 1051.
28. Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int 2005; 67: 278.
29. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46: 610.
30. Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1644.
31. Suresh E, Beadles W, Welsby P, Luqmani R. Acute pancreatitis with pseudocyst formation in a patient with polyarteritis nodosa. J Rheumatol 2005; 32: 386.
32. Khalifeh N, Haider D, Horl WH. Natriuretic peptides in chronic kidney disease and during renal replacement therapy: an update. J Investig Med 2009; 57: 33.
33. Saner FH, Plicht B, Treckmann J, et al. Tako-Tsubo syndrome as a rare cause of cardiac failure in liver transplantation. Liver Int 2010; 30: 159.
34. Pateron D, Beyne P, Laperche T, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999; 29: 640.